At $40,000 a month, this drug should perform better against more optimal control arms. Plus, RAS is a slippery little target. I think the efficacy of any anti-RAS drug will be time-limited given the tendency of tumors to rapidly adapt to new therapies.
RMC-6236-001 — NCT05379985 - Phase 1/2; advanced RAS-mutated solid tumors, especially PDAC and NSCLC; Daraxonrasib monotherapy, dose escalation 10–400 mg QD. Established 300 mg QD as the later-development dose and produced the first substantial efficacy signals. Still recruiting in some cohorts.
RASolve 301 — NCT06881784 - Phase 3; previously treated RAS-mutant NSCLC; Daraxonrasib vs docetaxel. Recruiting; approximately 420 patients planned. No Phase 3 efficacy results yet.
At $40,000 a month, this drug should perform better against more optimal control arms. Plus, RAS is a slippery little target. I think the efficacy of any anti-RAS drug will be time-limited given the tendency of tumors to rapidly adapt to new therapies.
Are there any studies/ results from G12C therapy for lung cancers and CRCs?
RMC-6236-001 — NCT05379985 - Phase 1/2; advanced RAS-mutated solid tumors, especially PDAC and NSCLC; Daraxonrasib monotherapy, dose escalation 10–400 mg QD. Established 300 mg QD as the later-development dose and produced the first substantial efficacy signals. Still recruiting in some cohorts.
RASolve 301 — NCT06881784 - Phase 3; previously treated RAS-mutant NSCLC; Daraxonrasib vs docetaxel. Recruiting; approximately 420 patients planned. No Phase 3 efficacy results yet.
I got this from https://clinicaltrials.gov/.